clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИ10.37489/2588-0519-2020-S4-35-38clinvest-523Research ArticleАКТУАЛЬНЫЕ ОБЗОРЫACTUAL REVIEWВозможность применения препарата тофацитиниб у пациентов с COVID-19Possibilities for the use of tofacitinib in patients with COVID-19https://orcid.org/0000-0002-6636-3950МатвеевА. В.MatveevA. V.

Матвеев Александр Витальевич – к. м. н., доцент кафедры клинической фармакологии и терапии. SPIN-код: 8518-1320

Москва

Matveev Alexander V. – Candidate of Medical Sciences, Associate Professor of the Department of Clinical Pharmacology and Therapy. SPIN code: 8518-1320

Moscow

https://orcid.org/0000-0002-6753-8572КиселёвЮ. Ю.KiselevYu. Yu.

Киселёв Юрий Юрьевич – PhD, доцент факультета наук о здоровье OsloMet

Осло

Kiselev Yuri Yu. – PhD, Associate Professor at the Faculty of Health Sciences OsloMet

Oslo

https://orcid.org/0000-0002-4496-3680СычёвД. А.SychevD. A.

Сычёв Дмитрий Алексеевич – д. м. н., профессор, член-корр. РАН, ректор, зав. кафедрой клинической фармакологии и терапии. SPIN-код: 4525-7556

Москва

Sychev Dmitry A. – Doctor of Medical Sciences, Professor, Corresponding Member RAS, Rector, Head. Department of Clinical Pharmacology and Therapy. SPIN code: 4525-7556

Moscow

dmitriy.alex.sychev@gmail.comФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy of Continuing Professional Education of the Ministry of Health of RussiaRussian FederationУниверситет Осло МетрополитенНорвегияOslo Metropolitan UniversityNorway20202710202004SФармаCOVID3538Copyright © Матвеев А.В., Киселёв Ю.Ю., Сычёв Д.А., 20202020Матвеев А.В., Киселёв Ю.Ю., Сычёв Д.А.Matveev A.V., Kiselev Y.Y., Sychev D.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/523

Не обнаружено исследований, оценивавших эффективность тофацитиниба в лечении COVID-19. Ряд профессиональных сообществ рекомендует прекратить терапию этим препаратом при выявлении инфекции SARS-CoV-2. Учитывая возможные осложнения применения тофацитиниба (инфекции, лимфопения, венозные тромбоэмболии и др.), его рутинное применение у пациентов с COVID-19 не может быть рекомендовано, кроме как в рамках клинических исследований у ограниченного круга пациентов под контролем подготовленного медицинского персонала.

No published trials measuring effectiveness of tofacitinib in COVID-19 have been identified. Some professional associations recommend discontinuing tofacitinib if SARS-CoV-2 infections is detected. Taken into account possible complications of the use of tofacitinib (infections, lymphopenia, venous thromboembolism), routine use of tofacitinib cannot be recommended unless within clinical trials under supervision of qualified healthcare professionals.

коронавирустофацитинибCOVID-19coronavirustofacitinibCOVID-19ReferencesArnaldez FI et al. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. J Immunother Cancer. 2020 May;8(1):e000930. DOI: 10.1136/jitc-2020-000930Arnaldez FI et al. The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response. J Immunother Cancer. 2020 May;8(1):e000930. DOI: 10.1136/jitc-2020-000930Gutin LS et al. Going Viral: Management of IBD in the Era of the COVID-19 Pandemic. Dig Dis Sci. 2020 Jun;65(6):1571-1575. DOI: 10.1007/s10620-020-06299-yGutin LS et al. Going Viral: Management of IBD in the Era of the COVID-19 Pandemic. Dig Dis Sci. 2020 Jun;65(6):1571-1575. DOI: 10.1007/s10620-020-06299-yJacobs J, Clark-Snustad K, Lee S. Case Report of a SARS-CoV-2 Infection in a Patient with Ulcerative Colitis on Tofacitinib. Inflamm Bowel Dis. 2020 Jun 18;26(7):e64. DOI: 10.1093/ibd/izaa093Jacobs J, Clark-Snustad K, Lee S. Case Report of a SARS-CoV-2 Infection in a Patient with Ulcerative Colitis on Tofacitinib. Inflamm Bowel Dis. 2020 Jun 18;26(7):e64. DOI: 10.1093/ibd/izaa093Kennedy NA et al. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut. 2020 Jun;69(6):984-990. DOI: 10.1136/gutjnl-2020-321244Kennedy NA et al. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut. 2020 Jun;69(6):984-990. DOI: 10.1136/gutjnl-2020-321244Khoo JK et al. Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis. Rheumatology (Oxford). 2020 Sep 1;59(9):2217-2225. DOI: 10.1093/rheumatology/keaa117Khoo JK et al. Pulmonary adverse events of small molecule JAK inhibitors in autoimmune disease: systematic review and meta-analysis. Rheumatology (Oxford). 2020 Sep 1;59(9):2217-2225. DOI: 10.1093/rheumatology/keaa117Liang H et al. Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the ass ociation with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting. RMD Open. 2019 23;5(2):e001013. DOI: 10.1136/rmdopen-2019-001013Liang H et al. Incidence of inpatient venous thromboembolism in treated patients with rheumatoid arthritis and the ass ociation with switching biologic or targeted synthetic disease-modifying antirheumatic drugs (DMARDs) in the real-world setting. RMD Open. 2019 23;5(2):e001013. DOI: 10.1136/rmdopen-2019-001013Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Rheumatology Science and Practice. 2019;57(1):8-16. DOI: 10.14412/1995-4484-2019-8-16Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Rheumatology Science and Practice. 2019;57(1):8-16. DOI: 10.14412/1995-4484-2019-8-16Rajaram S et al. The Promise and Peril of Natural Killer Cell Therapies in Pulmonary Infection. Immunity. 2020 Jun 13;52(6):887-889. DOI: 10.1016/j.immuni.2020.04.018Rajaram S et al. The Promise and Peril of Natural Killer Cell Therapies in Pulmonary Infection. Immunity. 2020 Jun 13;52(6):887-889. DOI: 10.1016/j.immuni.2020.04.018Sandborn WJ et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther. 2019 Nov;50(10):1068-1076. DOI: 10.1111/apt.15514Sandborn WJ et al. Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. Aliment Pharmacol Ther. 2019 Nov;50(10):1068-1076. DOI: 10.1111/apt.15514Sarzi-Puttini P et al. How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. Autoimmun Rev. 2020 Jul;19(7):102574. DOI: 10.1016/j.autrev.2020.102574Sarzi-Puttini P et al. How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. Autoimmun Rev. 2020 Jul;19(7):102574. DOI: 10.1016/j.autrev.2020.102574Tufan A et al. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020 Apr 21;50(SI-1):620-632. DOI: 10.3906/sag-2004-168Tufan A et al. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020 Apr 21;50(SI-1):620-632. DOI: 10.3906/sag-2004-168Wu C et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. DOI: 10.1001/jamainternmed.2020.0994Wu C et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. DOI: 10.1001/jamainternmed.2020.0994WHOCC — ATC/DDD Index [Электронный ресурс]. URL: https://www.whocc.no/atc_ddd_index/?code=L04AA29 (дата обращения: 15.05.2020).WHOCC — ATC/DDD Index [Электронный ресурс]. URL: https://www.whocc.no/atc_ddd_index/?code=L04AA29 (дата обращения: 15.05.2020).Государственный реестр лекарственных средств [Электронный ресурс]. URL: http://grls.rosminzdrav.ru/grls.aspx (дата обращения: 14.05.2020).Государственный реестр лекарственных средств [Электронный ресурс]. URL: http://grls.rosminzdrav.ru/grls.aspx (дата обращения: 14.05.2020).Государственный реестр лекарственных средств [Электронный ресурс]. URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=cf847781-be8b-4e94-801d-c0d49418b594&t= (дата обращения: 15.05.2020).Государственный реестр лекарственных средств [Электронный ресурс]. URL: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=cf847781-be8b-4e94-801d-c0d49418b594&t= (дата обращения: 15.05.2020).XELJANZ / XELJANZ XR (tofacitinib) [Электронный ресурс]. URL: https://www.pfizermedicalinformation.com/en-us/xeljanz/boxed-warning (дата обращения: 16.05.2020).XELJANZ / XELJANZ XR (tofacitinib) [Электронный ресурс]. URL: https://www.pfizermedicalinformation.com/en-us/xeljanz/boxed-warning (дата обращения: 16.05.2020).Xeljanz | European Medicines Agency [Электронный ресурс]. URL: https://www.ema.europa.eu/en/medicines/human/referrals/xeljanz (дата обращения: 15.05.2020).Xeljanz | European Medicines Agency [Электронный ресурс]. URL: https://www.ema.europa.eu/en/medicines/human/referrals/xeljanz (дата обращения: 15.05.2020).FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR) | FDA [Электронный ресурс]. URL: https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-aboutincreased-risk-blood-clots-and-death-higher-dose-arthritis-and (дата обращения: 15.05.2020).FDA approves Boxed Warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR) | FDA [Электронный ресурс]. URL: https://www.fda.gov/drugs/drug-safety-and-availability/fda-approves-boxed-warning-aboutincreased-risk-blood-clots-and-death-higher-dose-arthritis-and (дата обращения: 15.05.2020).

The authors declare that there are no conflicts of interest present.